
In an effort to settle the debate surrounding the use of ACE inhibitors (ACEI) and ARBs during the ongoing coronavirus disease 2019 (COVID-19) outbreak, investigators from Perelman School of Medicine at the University of Pennsylvania, recently launched a new clinical trial. The REPLACE COVID trial plans to recruit 152 hospitalized patients already taking medications from the classes, with the goal of determining whether discontinuing use affects the severity of disease symptoms.

































































































